{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:45:23Z","timestamp":1793389523392,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","award":["4011183"],"award-info":[{"award-number":["4011183"]}],"id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s10787-025-01919-3","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T15:42:16Z","timestamp":1756395736000},"page":"5583-5598","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The effects of ellagic acid in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: a randomized, add-on, double-blind, controlled trial"],"prefix":"10.1007","volume":"33","clinical-trial-number":[{"clinical-trial-number":"irct20180103038199n16","registry":"10.18810\/irct"}],"author":[{"given":"Mohammad Mahmoudi","family":"Azar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matin","family":"Shirazinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Nematy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vafa","family":"Baradaran Rahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motahare","family":"Bateni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fateme Tafaghodi Piadeh","family":"Gheibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farnood","family":"Rajabzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladan","family":"Goshayeshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Honari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehran","family":"Mottahedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9268-6270","authenticated-orcid":false,"given":"Vahid Reza","family":"Askari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"1919_CR1","doi-asserted-by":"publisher","DOI":"10.4062\/biomolther.2024.188","author":"H An","year":"2025","unstructured":"An H, Jang Y, Choi J, Hur J, Kim S, Kwon Y (2025) New insights into AMPK, as a potential therapeutic target in metabolic dysfunction-associated steatotic liver disease and hepatic fibrosis. Biomol Ther. https:\/\/doi.org\/10.4062\/biomolther.2024.188","journal-title":"Biomol Ther"},{"key":"1919_CR2","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1002\/ptr.7642","volume":"36","author":"SM Arabi","year":"2022","unstructured":"Arabi SM, Bahari H, Hamidipor S, Bahrami LS, Feizy Z, Nematy M, Kesharwani P, Sahebkar A (2022) The effects of curcumin-containing supplements on inflammatory biomarkers in hemodialysis patients: a systematic review and meta-analysis. Phytother Res 36:4361\u20134370","journal-title":"Phytother Res"},{"key":"1919_CR3","doi-asserted-by":"publisher","first-page":"e0214921","DOI":"10.1371\/journal.pone.0214921","volume":"14","author":"V Bachtiar","year":"2019","unstructured":"Bachtiar V, Kelly MD, Wilman HR, Jacobs J, Newbould R, Kelly CJ, Gyngell ML, Groves KE, McKay A, Herlihy AH (2019) Repeatability and reproducibility of multiparametric magnetic resonance imaging of the liver. PLoS ONE 14:e0214921","journal-title":"PLoS ONE"},{"key":"1919_CR4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/ptr.8404","volume":"39","author":"G Baghdadi","year":"2024","unstructured":"Baghdadi G, Shidfar F, Mokhtare M, Sarbakhsh P, Agah S (2024) Effect of pomegranate peel consumption on liver enzymes, lipid profile, liver steatosis, and hs-crp in patients with non-alcoholic fatty liver disease: a double-blind, placebo-controlled randomized clinical trial. Phytother Res 39:619\u2013629","journal-title":"Phytother Res"},{"key":"1919_CR5","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/ptr.6565","volume":"34","author":"V Baradaran Rahimi","year":"2020","unstructured":"Baradaran Rahimi V, Ghadiri M, Ramezani M, Askari VR (2020) Antiinflammatory and anti-cancer activities of pomegranate and its constituent, ellagic acid: evidence from cellular, animal, and clinical studies. Phytother Res 34:685\u2013720","journal-title":"Phytother Res"},{"key":"1919_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12937-023-00869-2","volume":"22","author":"H Barghchi","year":"2023","unstructured":"Barghchi H, Milkarizi N, Belyani S, Norouzian Ostad A, Askari VR, Rajabzadeh F, Goshayeshi L, Ghelichi Kheyrabadi SY, Razavidarmian M, Dehnavi Z, Sobhani SR, Nematy M (2023) Pomegranate (Punica granatum L.) peel extract ameliorates metabolic syndrome risk factors in patients with non-alcoholic fatty liver disease: a randomized double-blind clinical trial. Nutr J 22:40","journal-title":"Nutr J"},{"key":"1919_CR7","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.21105\/joss.02815","volume":"5","author":"MS Ben-Shachar","year":"2020","unstructured":"Ben-Shachar MS, L\u00fcdecke D, Makowski D (2020) Effectsize: estimation of effect size indices and standardized parameters. J Open Source Softw 5:2815","journal-title":"J Open Source Softw"},{"key":"1919_CR8","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/RCT.0b013e3181cefb89","volume":"34","author":"MA Bredella","year":"2010","unstructured":"Bredella MA, Ghomi RH, Thomas BJ, Ouellette HA, Sahani DV, Miller KK, Torriani M (2010) Breath-hold 1H-magnetic resonance spectroscopy for intrahepatic lipid quantification at 3 Tesla. J Comput Assist Tomogr 34:372\u2013376","journal-title":"J Comput Assist Tomogr"},{"key":"1919_CR9","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA (2016) The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65:1038\u20131048","journal-title":"Metabolism"},{"key":"1919_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-025-07670-6","author":"IW Chen","year":"2025","unstructured":"Chen IW, Hung KC (2025) Impact of probiotics on triglyceride level after bariatric surgery: a trial sequential analysis. Obes Surg. https:\/\/doi.org\/10.1007\/s11695-025-07670-6","journal-title":"Obes Surg"},{"key":"1919_CR11","volume-title":"Explaining psychological statistics","author":"BH Cohen","year":"2008","unstructured":"Cohen BH (2008) Explaining psychological statistics. John Wiley & Sons"},{"key":"1919_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12966-015-0162-z","volume":"12","author":"MR De Boer","year":"2015","unstructured":"De Boer MR, Waterlander WE, Kuijper LD, Steenhuis IH, Twisk JW (2015) Testing for baseline differences in randomized controlled trials: an unhealthy research behavior that is hard to eradicate. Int J Behav Nutr Phys Act 12:1\u20138","journal-title":"Int J Behav Nutr Phys Act"},{"key":"1919_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06196-3","author":"EASL","year":"2024","unstructured":"EASL, EASD, EASO (2024) EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): executive summary. Diabetologia. https:\/\/doi.org\/10.1007\/s00125-024-06196-3","journal-title":"Diabetologia"},{"issue":"1999\u20132014","key":"1919_CR14","first-page":"e1991","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J, Sanyal A, Neuschwander-Tetri B, Tiribelli C, Kleiner DE, Brunt E, Bugianesi E, Yki-J\u00e4rvinen H (2020) MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158(1999\u20132014):e1991","journal-title":"Gastroenterology"},{"key":"1919_CR15","doi-asserted-by":"publisher","first-page":"e080924","DOI":"10.1136\/bmj-2024-080924","volume":"387","author":"SG Flynn","year":"2024","unstructured":"Flynn SG, Park RS, Jena AB, Staffa SJ, Kim SY, Clarke JD, Pham IV, Lukovits KE, Huang SX, Sideridis GD (2024) Coaching inexperienced clinicians before a high stakes medical procedure: randomized clinical trial. BMJ 387:e080924","journal-title":"BMJ"},{"key":"1919_CR16","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ (2018) Mechanisms of NAFLD development and therapeutic strategies. Nat Med 24:908\u2013922","journal-title":"Nat Med"},{"key":"1919_CR17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2214\/AJR.11.7384","volume":"199","author":"P Georgoff","year":"2012","unstructured":"Georgoff P, Thomasson D, Louie A, Fleischman E, Dutcher L, Mani H, Kottilil S, Morse C, Dodd L, Kleiner D (2012) Hydrogen-1 MR spectroscopy for measurement and diagnosis of hepatic steatosis. AJR Am J Roentgenol 199:2\u20137","journal-title":"AJR Am J Roentgenol"},{"key":"1919_CR18","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/ptr.6867","volume":"35","author":"M Ghadimi","year":"2021","unstructured":"Ghadimi M, Foroughi F, Hashemipour S, Rashidi Nooshabadi M, Ahmadi MH, Ahadi Nezhad B, Khadem Haghighian H (2021) Randomized double-blind clinical trial examining the Ellagic acid effects on glycemic status, insulin resistance, antioxidant, and inflammatory factors in patients with type 2 diabetes. Phytother Res 35:1023\u20131032","journal-title":"Phytother Res"},{"key":"1919_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-024-03280-8","author":"H Ghazaee","year":"2024","unstructured":"Ghazaee H, Raouf Sheibani A, Mahdian H, Gholami S, Askari VR, Baradaran Rahimi V (2024) Ellagic acid as potential therapeutic compound for diabetes and its complications: a systematic review from bench to bed. Naunyn Schmiedebergs Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-024-03280-8","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1919_CR20","doi-asserted-by":"publisher","first-page":"m4743","DOI":"10.1136\/bmj.m4743","volume":"372","author":"JZ Goldenberg","year":"2021","unstructured":"Goldenberg JZ, Day A, Brinkworth GD, Sato J, Yamada S, J\u00f6nsson T, Beardsley J, Johnson JA, Thabane L, Johnston BC (2021) Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: systematic review and meta-analysis of published and unpublished randomized trial data. BMJ 372:m4743. https:\/\/doi.org\/10.1136\/bmj.m4743","journal-title":"BMJ"},{"key":"1919_CR21","doi-asserted-by":"publisher","first-page":"155094","DOI":"10.1016\/j.phymed.2023.155094","volume":"121","author":"G Hajiluian","year":"2023","unstructured":"Hajiluian G, Karegar SJ, Shidfar F, Aryaeian N, Salehi M, Lotfi T, Farhangnia P, Heshmati J, Delbandi AA (2023) The effects of Ellagic acid supplementation on neurotrophic, inflammation, and oxidative stress factors, and indoleamine 2, 3-dioxygenase gene expression in multiple sclerosis patients with mild to moderate depressive symptoms: a randomized, triple-blind, placebo-controlled trial. Phytomedicine 121:155094","journal-title":"Phytomedicine"},{"key":"1919_CR22","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.cgh.2018.06.011","volume":"17","author":"MAT Han","year":"2019","unstructured":"Han MAT, Altayar O, Hamdeh S, Takyar V, Rotman Y, Etzion O, Lefebvre E, Safadi R, Ratziu V, Prokop LJ, Murad MH, Noureddin M (2019) Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 17:616-629.e626","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1919_CR23","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","volume":"29","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Taub R, Neff GW, Lucas KJ, Labriola D, Moussa SE, Alkhouri N, Bashir MR (2023) Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med 29:2919\u20132928","journal-title":"Nat Med"},{"key":"1919_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11195741","volume":"11","author":"GM Hidalgo-Lozada","year":"2022","unstructured":"Hidalgo-Lozada GM, Villarruel-L\u00f3pez A, Mart\u00ednez-Abundis E, V\u00e1zquez-Paulino O, Gonz\u00e1lez-Ortiz M, P\u00e9rez-Rubio KG (2022a) Ellagic acid effect on the components of metabolic syndrome, insulin sensitivity and insulin secretion: a randomized, double-blind, placebo-controlled clinical trial. J Clin Med 11:5741","journal-title":"J Clin Med"},{"key":"1919_CR25","doi-asserted-by":"publisher","first-page":"5741","DOI":"10.3390\/jcm11195741","volume":"11","author":"GM Hidalgo-Lozada","year":"2022","unstructured":"Hidalgo-Lozada GM, Villarruel-L\u00f3pez A, Mart\u00ednez-Abundis E, V\u00e1zquez-Paulino O, Gonz\u00e1lez-Ortiz M, P\u00e9rez-Rubio KG (2022b) Ellagic acid effect on the components of metabolic syndrome, insulin sensitivity and insulin secretion: a randomized, double-blind placebo-controlled clinical trial. J Clin Med 11:5741","journal-title":"J Clin Med"},{"key":"1919_CR26","doi-asserted-by":"publisher","first-page":"e144775","DOI":"10.5812\/ijpbs-144775","volume":"18","author":"SH Hosseini","year":"2024","unstructured":"Hosseini SH, Zarghami M, Haghighian HK, Babaie A (2024) Effects of ellagic acid supplementation on antioxidant status and symptom improvement in patients with major depressive disorder: a double-blind randomized clinical trial. Iran J Psychiatry Behav Sci 18:e144775","journal-title":"Iran J Psychiatry Behav Sci"},{"key":"1919_CR27","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jep.2012.07.004","volume":"143","author":"T Ismail","year":"2012","unstructured":"Ismail T, Sestili P, Akhtar S (2012) Pomegranate peel and fruit extracts: a review of potential anti-inflammatory and anti-infective effects. J Ethnopharmacol 143:397\u2013405","journal-title":"J Ethnopharmacol"},{"key":"1919_CR28","doi-asserted-by":"publisher","first-page":"e058857","DOI":"10.1136\/bmjopen-2021-058857","volume":"12","author":"L Kakinami","year":"2022","unstructured":"Kakinami L, Smyrnova A, Paradis G, Tremblay A, Henderson M (2022) Comparison of different severe obesity definitions in predicting future cardiometabolic risk in a longitudinal cohort of children. BMJ Open 12:e058857","journal-title":"BMJ Open"},{"key":"1919_CR29","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3177\/jnsv.52.383","volume":"52","author":"K Kasai","year":"2006","unstructured":"Kasai K, Yoshimura M, Koga T, Arii M, Kawasaki S (2006) Effects of oral administration of ellagic acid-rich pomegranate extract on ultraviolet-induced pigmentation in the human skin. J Nutr Sci Vitaminol 52:383\u2013388","journal-title":"J Nutr Sci Vitaminol"},{"key":"1919_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41575-018-0082-x","volume":"16","author":"K Kazankov","year":"2019","unstructured":"Kazankov K, J\u00f8rgensen SMD, Thomsen KL, M\u00f8ller HJ, Vilstrup H, George J, Schuppan D, Gr\u00f8nb\u00e6k H (2019) The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 16:145\u2013159","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1919_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13048-021-00849-2","volume":"14","author":"M Kazemi","year":"2021","unstructured":"Kazemi M, Lalooha F, Nooshabadi MR, Dashti F, Kavianpour M, Haghighian HK (2021) Randomized double blind clinical trial evaluating the Ellagic acid effects on insulin resistance, oxidative stress and sex hormones levels in women with polycystic ovarian syndrome. J Ovarian Res 14:1\u201312","journal-title":"J Ovarian Res"},{"key":"1919_CR32","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1002\/hep.22109","volume":"47","author":"WR Kim","year":"2008","unstructured":"Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC (2008) Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 47:1363\u20131370","journal-title":"Hepatology"},{"key":"1919_CR33","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3350\/cmh.2024.0987","volume":"31","author":"D Kim","year":"2024","unstructured":"Kim D, Danpanichkul P, Wijarnpreecha K, Cholankeril G, Loomba R, Ahmed A (2024a) Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017\u20132023. Clin Mol Hepatol 31:382","journal-title":"Clin Mol Hepatol"},{"key":"1919_CR34","doi-asserted-by":"publisher","first-page":"1362391","DOI":"10.3389\/fphar.2024.1362391","volume":"15","author":"MH Kim","year":"2024","unstructured":"Kim MH, Ahn S, Hur N, Oh SY, Son CG (2024b) The additive effect of herbal medicines on lifestyle modification in the treatment of non-alcoholic fatty liver disease: a systematic review and meta-analysis. Front Pharmacol 15:1362391","journal-title":"Front Pharmacol"},{"key":"1919_CR35","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.3350\/cmh.2022.0351","volume":"29","author":"P Konyn","year":"2022","unstructured":"Konyn P, Ahmed A, Kim D (2022) Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease. Clin Mol Hepatol 29:S43","journal-title":"Clin Mol Hepatol"},{"key":"1919_CR36","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.crad.2019.02.014","volume":"74","author":"M Kromrey","year":"2019","unstructured":"Kromrey M, Ittermann T, Berning M, Kolb C, Hoffmann R, Lerch M, V\u00f6lzke H, K\u00fchn J-P (2019) Accuracy of ultrasonography in the assessment of liver fat compared with MRI. Clin Radiol 74:539\u2013546","journal-title":"Clin Radiol"},{"key":"1919_CR37","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/hep.31121","volume":"72","author":"R Loomba","year":"2020","unstructured":"Loomba R, Neuschwander-Tetri BA, Sanyal A, Chalasani N, Diehl AM, Terrault N, Kowdley K, Dasarathy S, Kleiner D, Behling C (2020) Multicenter validation of association between decline in MRI-PDFF and histologic response in NASH. Hepatology 72:1219\u20131229","journal-title":"Hepatology"},{"key":"1919_CR38","doi-asserted-by":"publisher","first-page":"597648","DOI":"10.3389\/fendo.2020.597648","volume":"11","author":"C Luci","year":"2020","unstructured":"Luci C, Bourinet M, Lecl\u00e8re PS, Anty R, Gual P (2020) Chronic inflammation in non-alcoholic steatohepatitis: molecular mechanisms and therapeutic strategies. Front Endocrinol 11:597648","journal-title":"Front Endocrinol"},{"key":"1919_CR39","doi-asserted-by":"crossref","unstructured":"Ma N, Bansal M, Chu J, Branch AD (2023) Much more than a name change: Impact of the new steatotic liver disease nomenclature on clinical algorithms and disease classification in US adults and adolescents. medRxiv: 2023.2008. 2004.23293664","DOI":"10.1101\/2023.08.04.23293664"},{"key":"1919_CR40","unstructured":"Mahmoudi Azar M, Bateni M, Tafaghodi Piadeh Gheibi F, Rajabzadeh F, Jafarzadeh Esfahani A, Goshayeshi L, Askari V, Nematy M (2024) Evaluation of The Effectiveness of Ellagic Acid on Liver Steatosis in Overweight\/Obese Non-Alcoholic Fatty Liver Disease Patients: Study Protocol for A Randomized Controlled Trial. Journal of Nutrition, Fasting and Health"},{"key":"1919_CR41","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1016\/j.metabol.2009.05.032","volume":"58","author":"M Mancini","year":"2009","unstructured":"Mancini M, Prinster A, Annuzzi G, Liuzzi R, Giacco R, Medagli C, Cremone M, Clemente G, Maurea S, Riccardi G (2009) Sonographic hepatic-renal ratio as indicator of hepatic steatosis: comparison with 1H magnetic resonance spectroscopy. Metabolism 58:1724\u20131730","journal-title":"Metabolism"},{"key":"1919_CR42","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor B, Treacher DF, Turner R (1985) Homeostasis model assessment: insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412\u2013419","journal-title":"Diabetologia"},{"key":"1919_CR43","doi-asserted-by":"publisher","first-page":"1371137","DOI":"10.3389\/fnut.2024.1371137","volume":"11","author":"N Milkarizi","year":"2024","unstructured":"Milkarizi N, Barghchi H, Belyani S, Bahari H, Rajabzade F, Ostad AN, Goshayeshi L, Nematy M, Askari VR (2024) Effects of Portulaca oleracea (purslane) on liver function tests, metabolic profile, oxidative stress and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: a randomized, double-blind clinical trial. Front Nutr 11:1371137","journal-title":"Front Nutr"},{"key":"1919_CR44","doi-asserted-by":"publisher","first-page":"98","DOI":"10.7762\/cnr.2022.11.2.98","volume":"11","author":"Z Mirzaie","year":"2022","unstructured":"Mirzaie Z, Bastani A, Haji-Aghamohammadi AA, Nooshabadi MR, Ahadinezhad B, Haghighian HK (2022a) Effects of ellagic acid on oxidative stress index, inflammatory markers and quality of life in patients with irritable bowel syndrome: randomized double-blind clinical trial. Clin Nutr Res 11:98","journal-title":"Clin Nutr Res"},{"key":"1919_CR45","doi-asserted-by":"publisher","first-page":"98","DOI":"10.7762\/cnr.2022.11.2.98","volume":"11","author":"Z Mirzaie","year":"2022","unstructured":"Mirzaie Z, Bastani A, Haji-Aghamohammadi AA, Rashidi Nooshabadi M, Ahadinezhad B, Khadem Haghighian H (2022b) Effects of ellagic acid on oxidative stress index, inflammatory markers and quality of life in patients with irritable bowel syndrome: randomized double-blind clinical trial. Clin Nutr Res 11:98\u2013109","journal-title":"Clin Nutr Res"},{"key":"1919_CR46","first-page":"1073","volume":"18","author":"MB Moghaddam","year":"2012","unstructured":"Moghaddam MB, Aghdam FB, Jafarabadi MA, Allahverdipour H, Nikookheslat SD, Safarpour S (2012) The Iranian version of International Physical Activity Questionnaire (IPAQ) in Iran: content and construct validity, factor structure, internal consistency and stability. World Appl Sci J 18:1073\u20131080","journal-title":"World Appl Sci J"},{"key":"1919_CR47","doi-asserted-by":"publisher","first-page":"206","DOI":"10.5009\/gnl20127","volume":"15","author":"S Murag","year":"2020","unstructured":"Murag S, Ahmed A, Kim D (2020) Recent epidemiology of nonalcoholic fatty liver disease. Gut and Liver 15:206","journal-title":"Gut and Liver"},{"key":"1919_CR48","doi-asserted-by":"publisher","first-page":"106492","DOI":"10.1016\/j.jff.2024.106492","volume":"122","author":"A Najmi","year":"2024","unstructured":"Najmi A, Nikrad N, Sarghein MG, Alizadeh M (2024) Ellagic acid supplementation on oxidative stress, antioxidative capacity and inflammation biomarkers: a systematic review and dose\u2013response meta-analysis of randomized controlled trials. J Funct Foods 122:106492","journal-title":"J Funct Foods"},{"key":"1919_CR49","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1089\/jmf.2013.2970","volume":"17","author":"KT Noh","year":"2014","unstructured":"Noh KT, Cha GS, Kim HC, Lee JH, Ahn SC, Kim DK, Park Y-M (2014) Ellagic acid modulates LPS-induced maturation of dendritic cells through the regulation of JNK activity. J Med Food 17:996\u20131002","journal-title":"J Med Food"},{"key":"1919_CR50","doi-asserted-by":"publisher","first-page":"e58777","DOI":"10.1371\/journal.pone.0058777","volume":"8","author":"J Olivier","year":"2013","unstructured":"Olivier J, Bell ML (2013) Effect sizes for 2\u00d7 2 contingency tables. PLoS ONE 8:e58777","journal-title":"PLoS ONE"},{"key":"1919_CR51","doi-asserted-by":"publisher","first-page":"6774","DOI":"10.1080\/03610926.2015.1134575","volume":"46","author":"J Olivier","year":"2017","unstructured":"Olivier J, May WL, Bell ML (2017) Relative effect sizes for measures of risk. Commun Stat-Theor Methods 46:6774\u20136781","journal-title":"Commun Stat-Theor Methods"},{"key":"1919_CR52","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1177\/1756283X16656735","volume":"9","author":"J Patel","year":"2016","unstructured":"Patel J, Bettencourt R, Cui J, Salotti J, Hooker J, Bhatt A, Hernandez C, Nguyen P, Aryafar H, Valasek M (2016) Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. Ther Adv Gastroenterol 9:692\u2013701","journal-title":"Ther Adv Gastroenterol"},{"key":"1919_CR53","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW-S, Rinella M (2021) Non-alcoholic fatty liver disease. Lancet 397:2212\u20132224","journal-title":"Lancet"},{"key":"1919_CR54","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/j.biopha.2018.10.024","volume":"108","author":"VB Rahimi","year":"2018","unstructured":"Rahimi VB, Askari VR, Mousavi SH (2018) Ellagic acid reveals promising anti-aging effects against d-galactose-induced aging on human neuroblastoma cell line, SH-SY5Y: a mechanistic study. Biomed Pharmacother 108:1712\u20131724","journal-title":"Biomed Pharmacother"},{"key":"1919_CR55","doi-asserted-by":"publisher","first-page":"116595","DOI":"10.1016\/j.lfs.2019.116595","volume":"232","author":"VB Rahimi","year":"2019","unstructured":"Rahimi VB, Askari VR, Mousavi SH (2019) Ellagic acid dose and time-dependently abrogates d-galactose-induced animal model of aging: investigating the role of PPAR-\u03b3. Life Sci 232:116595","journal-title":"Life Sci"},{"key":"1919_CR56","volume-title":"Krause and mahan\u2019s food and the nutrition care process e-book","author":"JL Raymond","year":"2020","unstructured":"Raymond JL, Morrow K (2020) Krause and mahan\u2019s food and the nutrition care process e-book. Elsevier Health Sciences"},{"key":"1919_CR57","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP (2023) A multisociety delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78:1966\u20131986","journal-title":"Hepatology"},{"key":"1919_CR58","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41575-019-0144-8","volume":"16","author":"AJ Sanyal","year":"2019","unstructured":"Sanyal AJ (2019) Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 16:377\u2013386","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1919_CR59","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/ijo.2017.210","volume":"42","author":"S Sherf-Dagan","year":"2018","unstructured":"Sherf-Dagan S, Zelber-Sagi S, Zilberman-Schapira G, Webb M, Buch A, Keidar A, Raziel A, Sakran N, Goitein D, Goldenberg N, Mahdi JA, Pevsner-Fischer M, Zmora N, Dori-Bachash M, Segal E, Elinav E, Shibolet O (2018) Probiotics administration following sleeve gastrectomy surgery: a randomized double-blind trial. Int J Obes (Lond) 42:147\u2013155","journal-title":"Int J Obes (Lond)"},{"issue":"156\u2013163","key":"1919_CR60","first-page":"e152","volume":"17","author":"MS Siddiqui","year":"2019","unstructured":"Siddiqui MS, Vuppalanchi R, Van Natta ML, Hallinan E, Kowdley KV, Abdelmalek M, Neuschwander-Tetri BA, Loomba R, Dasarathy S, Brandman D (2019) Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 17(156\u2013163):e152","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1919_CR61","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","volume":"70","author":"TG Simon","year":"2021","unstructured":"Simon TG, Roelstraete B, Khalili H, Hagstr\u00f6m H, Ludvigsson JF (2021) Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut 70:1375\u20131382","journal-title":"Gut"},{"key":"1919_CR62","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1001\/jama.2024.1215","volume":"331","author":"TG Simon","year":"2024","unstructured":"Simon TG, Wilechansky RM, Stoyanova S, Grossman A, Dichtel LE, Lauer GM, Miller KK, Hoshida Y, Corey KE, Loomba R (2024a) Aspirin for metabolic dysfunction-associated steatotic liver disease without cirrhosis: a randomized clinical trial. JAMA 331:920\u2013929","journal-title":"JAMA"},{"key":"1919_CR63","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1001\/jama.2024.1215","volume":"331","author":"TG Simon","year":"2024","unstructured":"Simon TG, Wilechansky RM, Stoyanova S, Grossman A, Dichtel LE, Lauer GM, Miller KK, Hoshida Y, Corey KE, Loomba R, Chung RT, Chan AT (2024b) Aspirin for metabolic dysfunction-associated steatotic liver disease without cirrhosis: a randomized clinical trial. JAMA 331:920\u2013929","journal-title":"JAMA"},{"key":"1919_CR64","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1002\/ptr.6937","volume":"35","author":"D Soleimani","year":"2021","unstructured":"Soleimani D, Rezaie M, Rajabzadeh F, Gholizadeh Navashenaq J, Abbaspour M, Miryan M, Razmpour F, Ranjbar G, Rezvani R, Jarahi L, Hashemy SI, Goshayeshi L, Nematy M (2021) Protective effects of propolis on hepatic steatosis and fibrosis among patients with nonalcoholic fatty liver disease (NAFLD) evaluated by real-time two-dimensional shear wave elastography: a randomized clinical trial. Phytother Res 35:1669\u20131679","journal-title":"Phytother Res"},{"issue":"2274\u20132283","key":"1919_CR65","first-page":"e2275","volume":"19","author":"JG Stine","year":"2021","unstructured":"Stine JG, Munaganuru N, Barnard A, Wang JL, Kaulback K, Argo CK, Singh S, Fowler KJ, Sirlin CB, Loomba R (2021) Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 19(2274\u20132283):e2275","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1919_CR66","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1136\/gutjnl-2021-324264","volume":"71","author":"N Tamaki","year":"2022","unstructured":"Tamaki N, Munaganuru N, Jung J, Yonan AQ, Loomba RR, Bettencourt R, Ajmera V, Valasek MA, Behling C, Sirlin CB (2022) Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. Gut 71:983\u2013990","journal-title":"Gut"},{"key":"1919_CR67","first-page":"691","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H (2024) MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut 73:691\u2013702","journal-title":"Gut"},{"key":"1919_CR68","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/hep.31518","volume":"73","author":"H Tilg","year":"2021","unstructured":"Tilg H, Adolph TE, Moschen AR (2021) Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: revisited after a decade. Hepatology 73:833\u2013842","journal-title":"Hepatology"},{"key":"1919_CR69","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","volume":"34","author":"G Vernon","year":"2011","unstructured":"Vernon G, Baranova A, Younossi Z (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34:274\u2013285","journal-title":"Aliment Pharmacol Ther"},{"key":"1919_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-1-6","volume":"1","author":"AJ Vickers","year":"2001","unstructured":"Vickers AJ (2001) The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study. BMC Med Res Methodol 1:1\u20134","journal-title":"BMC Med Res Methodol"},{"key":"1919_CR71","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2214\/AJR.07.4016","volume":"192","author":"M Webb","year":"2009","unstructured":"Webb M, Yeshua H, Zelber-Sagi S, Santo E, Brazowski E, Halpern Z, Oren R (2009) Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis. AJR Am J Roentgenol 192:909\u2013914","journal-title":"AJR Am J Roentgenol"},{"key":"1919_CR72","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/oby.2011.302","volume":"20","author":"MF Xia","year":"2012","unstructured":"Xia MF, Yan HM, He WY, Li XM, Li CL, Yao XZ, Li RK, Zeng MS, Gao X (2012) Standardized ultrasound hepatic\/renal ratio and hepatic attenuation rate to quantify liver fat content: an improvement method. Obesity 20:444\u2013452","journal-title":"Obesity"},{"key":"1919_CR73","doi-asserted-by":"publisher","first-page":"52","DOI":"10.14366\/usg.19013","volume":"39","author":"J Yoo","year":"2019","unstructured":"Yoo J, Lee JM, Joo I, Yoon JH (2019) Assessment of liver fibrosis using 2-dimensional shear wave elastography: a prospective study of intra-and inter-observer repeatability and comparison with point shear wave elastography. Ultrasonography 39:52","journal-title":"Ultrasonography"},{"key":"1919_CR74","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1017\/S0007114507666409","volume":"97","author":"Y-M Yu","year":"2007","unstructured":"Yu Y-M, Wang Z-H, Liu C-H, Chen C-S (2007) Ellagic acid inhibits IL-1\u03b2-induced cell adhesion molecule expression in human umbilical vein endothelial cells. Br J Nutr 97:692\u2013698","journal-title":"Br J Nutr"},{"key":"1919_CR75","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.3748\/wjg.v20.i15.4382","volume":"20","author":"S Zelber-Sagi","year":"2014","unstructured":"Zelber-Sagi S, Buch A, Yeshua H, Vaisman N, Webb M, Harari G, Kis O, Fliss-Isakov N, Izkhakov E, Halpern Z, Santo E, Oren R, Shibolet O (2014) Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial. World J Gastroenterol 20:4382\u20134392","journal-title":"World J Gastroenterol"},{"key":"1919_CR76","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1039\/C9FO00284G","volume":"10","author":"C Zhang","year":"2019","unstructured":"Zhang C, Hu J, Sheng L, Yuan M, Wu Y, Chen L, Wang G, Qiu Z (2019) Ellagic acid ameliorates AKT-driven hepatic steatosis in mice by suppressing de novo lipogenesis via the AKT\/SREBP-1\/FASN pathway. Food Funct 10:3410\u20133420","journal-title":"Food Funct"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01919-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-01919-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01919-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:07:22Z","timestamp":1758085642000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-01919-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":76,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1919"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-01919-3","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol for this study was approved by and according to the Research Ethics Committees of the Mashhad University of Medical Sciences (Code: IR.MUMS.MEDICAL.REC.1401.712) and was registered at the Iranian Registry of Clinical Trials (IRCT) (Identifier: IRCT20180103038199N16; ; (1\/5\/2023)). Moreover, written informed consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}]}}